Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (March 2026)
22 slides from Evofem Biosciences's investor presentation, Mar 11, 2026
Slide 1: Investor Presentation March 2026
E¥OFEM BIOSCIENCES INVESTOR PRESENTATION MARCH 2026 OTCID: EVFM
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” "will,” “should,” “expect,
Slide 3: Evofem Is Leading the Revolution
EVOFEM IS LEADING THE REVOLUTION OTCID: EVFM U.S. biopharma company commercializing innovative products to address unmet needs in women’s sexual and reproductive health Driving revenue growth from two FDA-approved sexual health products: First and only hormone-free, on demand prescription contracept
Slide 4: 26.2M Potential PHEXX Users in the U.S.
her” 26.2M POTENTIAL PHEXX USERS IN THE U.S.? { CONTRACEPTIVE USE AMONG WOMEN OF REPRODUCTIVE AGE (% Women using Method, U.S., 2022-2023; 74.9 M Women Aged 15-49) ? 9.8 M women use non-hormonal contraceptives Rx methods: PHEXX®, female condom, diaphragm Non-Rx methods: male condom; withdrawal; perio
Slide 5: PHEXX: Hormone Free Contraception
PHEXX: HORMONE FREE CONTRACEPTION WHAT MAKES PHEXX SO SPECIAL? * Vaginal pH Modulator * Hormone-free * FDA-approved for prevention of pregnancy * Can be used with other contraceptives! * Woman-controlled * Used only when you need it * Box of 12 pre-filled applicators, individually wrapped for conven
Slide 6: Every 1% Market Share in the U.S. Addressable Market
fet EVERY 1% MARKET SHARE IN THE U.S. ADDRESSABLE MARKET Pp Y REPRESENTS SIGNIFICANT PHEXX NET PRODUCT SALES $380.28 GROSS WAC per box of 12 PHEXX applicators BOXES OF PHEXX =, - om dispensed (on avg.) mo a, PHEXX ANNUAL per woman each year... Se NET SALES = o> K 262, 000 ~ per each 1% market penetr
Slide 7: Five Consecutive Years of Net Sales Growth
FIVE CONSECUTIVE YEARS OF NET SALES GROWTH IN MILLIONS $250 $200 $150 $100 — FY 2020 Launched PHEXX Sept. 2020 $8.2 FY 2021 $16.8 FY 2022 $19.4 $18.2 FY 2023 FY 2024 No marketing spend since Q4 2022 $20.2 FY 2025 March 11, 2026 7
Slide 8: PHEXX Sales Coverage
PHEXX SALES COVERAGE || Field Coverage (n=16) Virtual Coverage G Strategic Initiatives les] Student Health & Residency Programs
Slide 9: Activating PHEXX Utilization with Select Patient Types
ACTIVATING PHEXX UTILIZATION WITH SELECT PATIENT TYPES ~ i * Not using a prescription contraceptive Living with depression and anxiety Postpartum mother Struggles with her weight In need of non-systemic contraception Cancer survivor Wants non-hormonal WE ARE SUCCESSFULLY REACHING OUR TARGET PATIENT
Slide 10: Creating the Vaginal pH Modulator Category
CREATING THE VAGINAL PH MODULATOR CATEGORY Changing the contraceptive counseling conversation to make it personal OS0O0® fe eeaalelsl NASINAL BH conoom SPERMICIDE Fkenne _compeniuo—Tuaas USATION HORMONE FREE Eltui) Conhiners CONTAINS HORMONES IS PERSONAL. WHICH METHOD MEETS YOUR NEEDS? SPERMICIDE BI
Slide 11: Harnessing the Power of Social Media
HARNESSING THE POWER OF SOCIAL MEDIA Social media is an effective channel to reach women ages 18 to 49 * 39% of women ages 18 to 49 have seen / heard something on social media about birth control 4 * 19% talked to someone in their life about what they heard / saw Reach and impact even higher in the
Slide 12: "Say Vagina" Campaign
“SAY VAGINA” CAMPAIGN COMBAT MEDIA CENSORSHIP AND NORMALIZE USE OF PROPER MEDICAL TERMS IN WOMEN’S HEALTH Say Vagina Through this bold public campaign Evofem shared content across { our social media accounts in August 2025 educating people on the vagina and how to properly care for it. 2 i | We laun
Slide 13: Multichannel Marketing
MULTICHANNEL MARKETING Enhancing promotional reach with minimal spend by tapping into social media, key conference opportunities, and tactical collateral Phexx’ In Vitro Demonstration of Sperm Motility 6= 6G ae D = Hormone-Free Birth Control soem ence birth Control $i @Qo== © pees. o _. eee Empoweri
Slide 14: Single-Dose Oral Treatment for Two Common Sexual Health Conditions
£ SINGLE-DOSE ORAL TREATMENT FOR _>=— solosec TWO COMMON SEXUAL HEALTH CONDITIONS a secnidazole 2g Oral Granules * Acquired in July 2024 from Lupin, re-launched in November 2024 * Synergistic sexual health product aligns with our strategic focus and leverages sales force SOLOSEC provides a complete
Slide 15: The GLP-1 Opportunity: $877 Million TAM
THE GLP-1 OPPORTUNITY: $877 MILLION TAM ~15.77M Women of Reproductive Age in the U.S. report GLP-1 Usage +2 3.55 M Women on GLP-1s using OCs 2,206,745 oe 13,563,916 These women are instructed to use a supplemental, hormone- free method for 4 weeks after initiating GLP-1 use and for 4 weeks after eac
Slide 16: Strong IP with Multiple Orange Book-Listed Patents
STRONG IP WITH MULTIPLE ORANGE BOOK-LISTED PATENTS *or pr solosec a secnidazole 2g Oral Granules Four Orange Book- listed patents afford protection into 2033 White paper by US regulatory expert* delineates hurdles to potential generic entry stemming from PHEXX’s localized MOA and absence of PK profi
Slide 17: Improving Our Financials Through Three Ongoing Initiatives
IMPROVING OUR FINANCIALS THROUGH THREE ONGOING INITIATIVES 1. EXPANDING REVENUE STREAM WITH EX-U.S. SALES 2. LOWERING SOLOSEC COGS * Goal — reduce SOLOSEC COGS by 55% to 60% starting 2027 3. LOWERING PHEXX COGS * Goal — reduce PHEXX COGS by 55% to 60% with new manufacturer, once FDA-cleared March 11
Slide 18: Expanding Globally
EXPANDING GLOBALLY FIRST OUS TERRITORY: MIDDLE EAST/NORTH AFRICA (MENA) License and Supply agreements with Emirati health care company Pharma 1 Drug Store, LLC, for PHEXX and SOLOSEC signed July 2024 and May 2025, respectively. * Pharma 1 has exclusive commercialization rights in the Territory, and
Slide 19: First Market in Territory: United Arab Emirates
FIRST MARKET IN TERRITORY: UNITED ARAB EMIRATES (UAE) * 3.8 million women in UAE + * A 2019 contraceptive use study found 56% of women in UAE were using non-prescription methods (condom, withdrawal, sponge, calendar, and N-9 spermicide) 2 Fr ¢* Application for marketing approval in UAE was submitted
Slide 20: Lowering PHEXX COGS
LOWERING PHEXX COGS Identified and engaged an OUS manufacturer for PHEXX in 2025. PHEXX COGS are expected to decrease by 55% to 60% from current levels a once we are selling goods produced by new manufacturer. € "eb & * Process Timin * Tech transfer to new manufacturer underway « ¢ Manufacture valid
Slide 21: Lowering SOLOSEC COGS
LOWERING SOLOSEC COGS Evofem is currently reactivating the SOLOSEC supply chain SOLOSEC COGS are expected to be 55% to 60% lower once we transition from selling legacy product to new-made goods Process Timin v Source API supply complete * Receive raw secnidazole Q4 2026 te * Manufacture SOLOSEC gran
Slide 22: In Summary
IN SUMMARY We are executing our strategy to improve women’s lives through innovative sexual and reproductive health products that address unmet and underserved medical needs Y- pret The first and only FDA-approved hormone-free, on demand prescription contraceptive « vaginal gel - Approved and launch
Evofem Biosciences — Investor Presentation (March 2026) on 6ix